Preclinical comparison of [
PSMA
Prostate cancer
Radiohybrid
Radioligand therapy
rhPSMA
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
26 Feb 2024
26 Feb 2024
Historique:
received:
18
01
2024
accepted:
20
02
2024
medline:
26
2
2024
pubmed:
26
2
2024
entrez:
26
2
2024
Statut:
epublish
Résumé
Radiohybrid PSMA-targeted ligands (rhPSMA) have been introduced as a novel platform for theranostic applications. Among a variety of rhPSMA-ligands developed for radioligand therapy, two stereoisomers [ rhPSMA-10.1 and -10.2 were radiolabeled with lutetium-177 according to the established procedures of other DOTA-based PSMA ligands and displayed a high and comparable stability in all buffers and human serum (> 97%, 24 h). Biodistribution studies revealed fast clearance from the blood pool (0.3-0.6%ID/g at 1 h) and other background tissues within 48 h. Distinctive differences were found in the kidneys, where [ Our preclinical data on biodistribution and dosimetry indicate a more favorable profile of [
Sections du résumé
BACKGROUND
BACKGROUND
Radiohybrid PSMA-targeted ligands (rhPSMA) have been introduced as a novel platform for theranostic applications. Among a variety of rhPSMA-ligands developed for radioligand therapy, two stereoisomers [
RESULTS
RESULTS
rhPSMA-10.1 and -10.2 were radiolabeled with lutetium-177 according to the established procedures of other DOTA-based PSMA ligands and displayed a high and comparable stability in all buffers and human serum (> 97%, 24 h). Biodistribution studies revealed fast clearance from the blood pool (0.3-0.6%ID/g at 1 h) and other background tissues within 48 h. Distinctive differences were found in the kidneys, where [
CONCLUSION
CONCLUSIONS
Our preclinical data on biodistribution and dosimetry indicate a more favorable profile of [
Identifiants
pubmed: 38407630
doi: 10.1186/s41181-024-00246-2
pii: 10.1186/s41181-024-00246-2
doi:
Banques de données
ClinicalTrials.gov
['NCT06105918']
Types de publication
Journal Article
Langues
eng
Pagination
18Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 824
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 824
Informations de copyright
© 2024. The Author(s).
Références
Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914–20.
doi: 10.2967/jnumed.114.147413
pubmed: 25883127
Buxbaum JN, Reixach N. Transthyretin: the servant of many masters. Cell Mol Life Sci. 2009;66(19):3095–101.
doi: 10.1007/s00018-009-0109-0
pubmed: 19644733
pmcid: 4820353
Deberle LM, Benešová M, Umbricht CA, Borgna F, Büchler M, Zhernosekov K, et al. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. 2020;10(4):1678–93.
doi: 10.7150/thno.40482
pubmed: 32042329
pmcid: 6993238
Derks YHW, Löwik D, Sedelaar JPM, Gotthardt M, Boerman OC, Rijpkema M, et al. PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. Theranostics. 2019;9(23):6824–39.
doi: 10.7150/thno.36739
pubmed: 31660071
pmcid: 6815946
Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29(9):1651–7.
doi: 10.1158/1078-0432.CCR-22-2875
pubmed: 36469000
pmcid: 10159870
Feuerecker B, Chantadisai M, Allmann A, Tauber R, Allmann J, Steinhelfer L, et al. Pre-therapeutic comparative dosimetry of (177)Lu-rhPSMA-7.3 and (177)Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC). J Nucl Med. 2021;63(6):833–9.
doi: 10.2967/jnumed.121.262671
pubmed: 34531260
Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(6):920–6.
doi: 10.1016/j.eururo.2018.11.016
pubmed: 30473431
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, et al. Diagnostic performance and safety of (18)F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). Reply. J Urol. 2023. https://doi.org/10.1097/ju.0000000000003598 .
doi: 10.1097/ju.0000000000003598
pubmed: 37416959
Knorr K, Oh SW, Krönke M, Wurzer A, D’Alessandria C, Herz M, et al. Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3. EJNMMI Res. 2022;12(1):8.
doi: 10.1186/s13550-021-00872-w
pubmed: 35119557
pmcid: 8816989
Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad Berka experience since 2013. J Nucl Med. 2016;57(Suppl 3):97s–104s.
doi: 10.2967/jnumed.115.170167
pubmed: 27694180
Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, et al. (177)Lu-labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio. J Nucl Med. 2021;62(4):521–7.
doi: 10.2967/jnumed.120.250738
pubmed: 32859704
pmcid: 8049373
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90.
doi: 10.2967/jnumed.116.183194
pubmed: 27765862
Roopenian DC, Low BE, Christianson GJ, Proetzel G, Sproule TJ, Wiles MV. Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. Mabs. 2015;7(2):344–51.
doi: 10.1080/19420862.2015.1008345
pubmed: 25654695
pmcid: 4623309
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103.
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, et al. Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. J Nucl Med. 2019;60(1):71–8.
doi: 10.2967/jnumed.118.212720
pubmed: 30237214
pmcid: 6354225
Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63(8):1199–207.
doi: 10.2967/jnumed.121.262713
pubmed: 34887335
pmcid: 9364353
Smith SA, Waters NJ. Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein. Pharm Res. 2018;36(2):30.
doi: 10.1007/s11095-018-2551-x
pubmed: 30593605
pmcid: 7089466
Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med. 2000;41(1):149–60.
pubmed: 10647618
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023–7.
pubmed: 15937315
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, et al. Diagnostic performance and safety of positron emission tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol. 2023;84:361–70.
doi: 10.1016/j.eururo.2023.06.018
pubmed: 37414702
Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov. 2008;7(1):84–99.
doi: 10.1038/nrd2353
pubmed: 18079757
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56(8):1169–76.
doi: 10.2967/jnumed.115.158550
pubmed: 26089548
Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, et al. Radiohybrid ligands: a novel tracer concept exemplified by (18)F- or (68)Ga-labeled rhPSMA inhibitors. J Nucl Med. 2020a;61(5):735–42.
doi: 10.2967/jnumed.119.234922
pubmed: 31862804
pmcid: 7198388
Wurzer A, Parzinger M, Konrad M, Beck R, Günther T, Felber V, et al. Preclinical comparison of four [(18)F, (nat)Ga]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics. EJNMMI Res. 2020b;10(1):149.
doi: 10.1186/s13550-020-00740-z
pubmed: 33284394
pmcid: 7721954
Wurzer A, Kunert JP, Fischer S, Felber V, Beck R, De Rose F, et al. Synthesis and preclinical evaluation of (177)Lu-labeled radiohybrid PSMA ligands (rhPSMAs) for endoradiotherapy of prostate cancer. J Nucl Med. 2022;63(10):1489–95.
doi: 10.2967/jnumed.121.263371
pubmed: 35086894
pmcid: 9536713
Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(9):1473–9.
doi: 10.1007/s00259-017-3681-9
pubmed: 28337529
Yuan J. Estimation of variance for AUC in animal studies. J Pharm Sci. 1993;82(7):761–3.
doi: 10.1002/jps.2600820718
pubmed: 8360854
Yusufi N, Wurzer A, Herz M, D’Alessandria C, Feuerecker B, Weber W, et al. Comparative preclinical biodistribution, dosimetry, and endoradiotherapy in metastatic castration-resistant prostate cancer using (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T. J Nucl Med. 2021;62(8):1106–11.
doi: 10.2967/jnumed.120.254516
pubmed: 33443072